BRISBANE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that Cameron Durrant, MD, chairman and CEO, will present a company overview at two investor conferences in early June.

Details of the presentations follow:

Primary Capital, The Investor Conference Date: Sunday, June 4, 2017 Location: The Resort at Pelican Hill, Newport Beach, Calif.

7th Annual LD Micro Invitational Date: Tuesday, June 6, 2017, 1:30 p.m. PT Track: 5 Location: Luxe Sunset Boulevard Hotel, Los Angeles, Calif.

In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, contact MZ Group at mike.cole@mzgroup.us.

About KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT:Investors:Mike ColeO: 949-259-4988C: 949-444-1341mike.cole@mzgroup.usMedia:Lisa GuitermanO: 301-217-9353C: 202-330-3431media@kalobios.com

Primary Logo

If you liked this article you might like

KaloBios Pharmaceuticals, Potash and Radian: Doug Kass' Views

Stocks Slip on 2016 Outlook of Middling Economic Growth

Energy Lags Wall Street as Crude Oil Spirals Lower

KaloBios Looks to Restructure While Under Court Protection in Delaware

KaloBios Pharmaceuticals (KBIO) Files For Bankruptcy, Stock Delisted From Nasdaq